@Article{oncologie.2022.022299,
AUTHOR = {Dariimaa Ganbat, Bat-Erdene Jugder, Lkhamaa Ganbat, Miki Tomoeda, Erdenetsogt Dungubat, Ambaga Miyegombo, Gantsetseg Garmaa, Yoshihisa Takahashi, Ryuji Fukuzawa, Ichiro Mori, Takayuki Shiomi, Akinori Nakata, Yasuhiko Tomita},
TITLE = {Use of the Naphthoquinone YM155 (Sepantronium Bromide) in the Treatment of Cancer: A Systematic Review and Meta-Synthesis},
JOURNAL = {Oncologie},
VOLUME = {24},
YEAR = {2022},
NUMBER = {2},
PAGES = {195--225},
URL = {http://www.techscience.com/oncologie/v24n2/48746},
ISSN = {1765-2839},
ABSTRACT = {Most cancer cells overexpress the anti-apoptotic protein survivin and display redox dysregulation originating
from genotypic and phenotypic alterations. These disturbances contribute to the uncontrolled proliferation, invasion, and chemoresistance of cancer cells, yet they also represent a specific vulnerability that could be exploited
therapeutically in selected tumors. YM155 (sepantronium bromide) is a naphthoquinone-containing imidazolebased compound that selectively inhibits survivin expression at the transcriptional and post-transcriptional levels.
Here, we performed a systematic review and meta-analysis of clinical studies in which YM155 was administered
as monotherapy or combination therapy for patients with cancer. We assessed fully or partially reported clinical
outcomes and pharmacological parameters, and further performed subgroup analysis based on tumor type and
treatment regimen. Our comprehensive analysis, which included patients of many ethnicities, demonstrated that
YM155 was effective as a monotherapy or combination therapy. Clinical benefits, including regression and/or stabilization of tumor progression and prolonged survival, were observed within a reasonable time after treatment
initiation, and YM155 displayed good synergistic effects with combination drugs. YM155 appears to be effective
against a wide range of tumor types and has an acceptable safety profile, with the main toxicities being decreased
blood cell counts; fatigue/weakness; renal, hepatic, and/or cardiac issues; and electrolyte disturbance.},
DOI = {10.32604/oncologie.2022.022299}
}